A vaccine developed at New York City-based Memorial Sloan Kettering Cancer Center lowered the risk of death by 41% for patients in remission from acute myeloid leukemia in a phase 3 trial.
Among the 126 patients in the trial, those who received the vaccine, galinpepimut-S, had a median overall survival of 24 months, compared with 14.7 months for those on standard treatments, according to a Nov. 17 news release from the cancer center.
David Scheinberg, MD, PhD, chairman of the Experimental Therapeutics Center at Memorial Sloan Kettering and deputy director of therapeutic discovery at Sloan Kettering Institute — the basic and translational biomedical research arm of Memorial Sloan Kettering — has been leading development of the vaccine with colleagues for more than 20 years, the release said.
